In the news

As lifespans grow longer, targeted medical technology can help people live better, healthier lives—with fewer pills.

Dr. Janar Sathananthan, president, Interventional Cardiology, discusses the FRACTURE IDE trial, which met its primary endpoints for the SEISMIQ™ 4CE Coronary IVL Catheter in severely calcified coronary disease. The result underscores Boston Scientific’s broader intravascular lithotripsy commercialization strategy and differentiated cardiology solutions.

Karen Carlson’s incontinence kept her housebound for years despite various failed treatments. The Axonics™ Sacral Neuromodulation Therapy helped relieve her symptoms, restoring her active life.

This sponsored article explores how physicians are helping patients living with atrial fibrillation address two health issues at the same time: irregular heart rhythms and stroke risk.

The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.

Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.

The VAPEUR clinical trial compared Rezūm™ Water Vapor Therapy to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in sexually active men. Key findings from the study demonstrate that Rezūm Therapy provides superior BPH symptom relief versus combination therapy while preserving sexual function.

Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.

Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Learn how Boston Scientific consistently achieved superior results while minimizing distressing organizational transformations by creating and continually cultivating the business equivalent of a thriving, adaptive biological ecosystem.